Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.

Abstract

Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen without rituximab. In the present study, we aim to re-assess the prognostic significance of serum sIL-2R for diffuse large B cell lymphoma (DLBCL) patients treated with CHOP plus rituximab and to assess sIL-2R with subtype of DLBCL, such as GCB type and non-GCB type. Two hundred and thirty-three patients with DLBCL were enrolled between December 2002 and March 2008. To evaluate serum levels of sIL-2R, venous blood samples were drawn from patients immediately before initiation of treatment. Serum sIL-2R was determined by sandwich enzyme-linked immunosorbent assay. The 5-year overall survival (OS) rates for patients with sIL-2R levels of ≥2,000 (110 cases) and <2,000 U/mL (123 cases) were 54.2% and 89.0% (P < 0.0001), respectively. Multivariate analysis using the proportional-hazards model revealed that serum sIL-2R (P = 0.0099) and extranodal involvement sites (P = 0.0392) were independent prognostic factors for OS and that clinical stage (P = 0.0168), performance status (P = 0.0181), sIL-2R (P = 0.0232), and LDH (P = 0.0316) were independent prognostic factors for progression-free survival in sIL-2R and every factor of the International Prognostic Index. Serum sIL-2R might be a useful prognostic factor for DLBCL patients in the rituximab era.

• Authors: Naoe Goto, Hisashi Tsurumi, Hideko Goto, Yoriko Ino Shimomura, Senji Kasahara, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Takeshi Yoshikawa, Kenji Fukuno, Takeshi Takahashi, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki
• Journal: Annals of hematology (Ann Hematol) Vol. 91 Issue 5 Pg. 705-714 (May 2012) ISSN: 1432-0584 [Electronic] Germany
• PMID: 22183251 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• R-CHOP protocol
• Receptors, Interleukin-2
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Humans
• Immunophenotyping
• Lymphoma, Large B-Cell, Diffuse (blood, drug therapy, mortality)
• Male
• Prednisone (therapeutic use)
• Prognosis
• Receptors, Interleukin-2 (blood)
• Reference Values
• Remission Induction
• Rituximab
• Survival Analysis
• Treatment Outcome
• Vincristine (therapeutic use)